Pulse Biosciences Inc Stock Price, News & Analysis

Pulse Biosciences (PLSE) reported its Q2 2021 financial results, highlighting significant developments in its CellFX System's launch and clinical trials. By the end of Q2, 49 clinics participated in the Controlled Launch Program, with 34 onboarded in that quarter. The company achieved Health Canada approval and initiated Canadian operations. Financially, cash reserves decreased to $47.4 million, with a net loss of $15.3 million. Non-GAAP operating expenses rose to $12.1 million, driven by increased commercialization efforts.

Pulse Biosciences (Nasdaq: PLSE) will release its financial results for Q2 2021 after market close on August 9, 2021. A conference call led by management will follow at 1:30 PM PT. The company focuses on Nano-Pulse Stimulation™ (NPS™) technology, with its CellFX® System being the first commercial product designed for dermatologic applications, allowing for the non-thermal treatment of cells while preserving surrounding tissue. This multi-application platform adopts a utilization-based revenue model, intending to elevate patient outcomes.

Pulse Biosciences (Nasdaq: PLSE) has entered a stock purchase agreement with Robert W. Duggan for 3,048,780 shares at $16.40 each. This deal will clear $41.6 million in debt owed to Duggan, who will invest an additional $8.4 million. Following this transaction, Duggan's ownership will rise to 51% of the company, making it a controlled entity. The funds will support the CellFX System Controlled Launch Program and expand clinical applications for Nano-Pulse Stimulation technology. The closing is expected by July 7, 2021.

Pulse Biosciences, Inc. (Nasdaq: PLSE) announces the first Canadian patient has been treated with the CellFX System, utilizing Nano-Pulse Stimulation (NPS) technology. This significant milestone expands their Controlled Launch program in North America and Europe, enhancing clinical applications for aesthetic dermatology. Dr. Sheetal Sapra, a leading dermatologist, highlights the potential benefits of this novel procedure for patients with common skin lesions. The CellFX System is expected to improve patient outcomes and drive growth, backed by a strategic rollout across major Canadian metropolitan areas.

Pulse Biosciences (Nasdaq: PLSE) has received Health Canada approval for its CellFX® System, enabling its use in dermatological procedures targeting benign lesions, such as sebaceous hyperplasia and warts. This regulatory approval marks a significant milestone, following previous clearances from the FDA and CE mark earlier this year. The company plans to expand its controlled launch of CellFX across select Canadian medical practices and aims to recruit approximately 80 participating practices in North America and Europe. The CellFX System utilizes Nano-Pulse Stimulation™ technology to non-thermally clear targeted cells.

Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 2, 2021, at 12:30pm PT. The company is known for its innovative CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, designed to treat various dermatologic conditions effectively. The CellFX System represents a significant advancement in bioelectric medicine, offering a non-thermal method that targets specific cells while preserving surrounding tissues. Interested viewers can access the webcast through the company’s website.

Pulse Biosciences (Nasdaq: PLSE) announced the presentation of four clinical studies on its Nano-Pulse Stimulation (NPS) technology at the ASLMS Virtual Annual Meeting on May 15-16, 2021. The studies focus on treating benign skin lesions, including back acne, common nevi, sebaceous hyperplasia, and cutaneous warts. The NPS technology demonstrated promising efficacy, with significant lesion clearance rates and minimal skin effects. Results suggest NPS could meet unmet medical needs in dermatology. The company's commitment to innovation in bioelectric medicine is highlighted by these advancements.

Pulse Biosciences (PLSE) reported its Q1 2021 financial results, highlighting significant progress in the rollout of its CellFX System Controlled Launch program, onboarding 15 aesthetic practices. The company submitted a final response to Health Canada for the CellFX System Medical Device License, with completion expected by Q2. FDA IDE approval was received for a feasibility study on basal cell carcinoma treatment. Financially, cash and investments reached $59.9 million, though GAAP net loss increased to $18.6 million from $11.9 million YoY, reflecting rising operational expenses.

Pulse Biosciences, Inc. (Nasdaq: PLSE) is set to report its first-quarter 2021 financial results on May 10, 2021, post-market close. A conference call will follow at 1:30 PM PT, where management will discuss the financial outcomes. Interested investors can join by dialing the provided numbers or by accessing the webcast available on the company's investor relations website. Pulse Biosciences is dedicated to advancing its Nano-Pulse Stimulation™ (NPS™) technology, notably through its CellFX® System, which targets dermatologic conditions while ensuring non-thermal clearance of cells.